MT 3724

Drug Profile

MT 3724

Alternative Names: MT3724

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Molecular Templates
  • Developer Banner MD Anderson Cancer Center; Molecular Templates
  • Class Antibodies; Antineoplastics; Bacterial toxins; Immunoconjugates
  • Mechanism of Action CD20 antigen inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Dec 2016 Updated efficacy and adverse event data from a phase I trial in non-Hodgkin's B-cell lymphoma (Second line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 16 Apr 2016 Interim efficacy and adverse event data from a phase I trial in non-Hodgkin's B-cell lymphoma (Second line therapy or greater) presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 29 Feb 2016 Molecular Templates withdraws a phase I trial for Chronic lymphocytic leukaemia and Small lymphocytic leukaemia (Second-line therapy or greater) in USA (NCT02556346)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top